Table 1.
Baseline characteristics of 159 participants with inflammatory bowel disease
| Characteristic | Women (n = 85) | Men (n = 74) |
|---|---|---|
| Crohn’s disease | 54 (64) | 43 (58) |
| Disease characteristics | ||
| Montreal classification for Crohn’s disease | ||
| A1 | 4 (47) | 32 (74) |
| A2 | 42 (49) | 7 (16) |
| A3 | 8 (9) | 4 (9) |
| L1 | 12 (14) | 6 (14) |
| L2 | 11 (13) | 10 (23) |
| L3 | 31 (36) | 27 (63) |
| B1 | 33 (61) | 27 (63) |
| B2 | 15 (28) | 5 (12) |
| B3 | 6 (11) | 11 (25) |
| P | 8 (9) | 7 (9) |
| Montreal classification for ulcerative colitis | ||
| A1 | 0 (0) | 0 (0) |
| A2 | 10 (32) | 6 (19) |
| A3 | 21 (68) | 25 (81) |
| E1 | 4 (13) | 2 (7) |
| E2 | 14 (45) | 14 (45) |
| E3 | 13 (42) | 15 (48) |
| Age, y | 48 (39-62) | 43 (33-54) |
| Time since diagnosis, y | 10 (4-21) | 14 (8-23) |
| Medication use | ||
| Current corticosteroids | 13 (15) | 15 (20) |
| Corticosteroid use in last year | 29 (34) | 24 (32) |
| Immunomodulator | 32 (38) | 31 (42) |
| Biologic | 21 (25) | 14 (19) |
| Psychotropic | 27 (32) | 8 (11) |
| Antihypertensives | 5 (6) | 15 (20) |
| Hormonal contraceptive | 14 (16) | — |
| Previous depression diagnosis | 18 (21) | 5 (7) |
| Previous anxiety diagnosis | 12 (14) | 2 (3) |
| Other major comorbiditya | 23 (27) | 9 (12) |
| Irritable bowel syndrome | 12 (14) | 1 (1) |
| Previous bowel resection | 21 (25) | 16 (22) |
| Active perianal diseaseb | 6 (7) | 4 (5) |
| Excess alcohol intakec | 3 (4) | 3 (4) |
| Opiate use | 8 (9) | 2 (3) |
| Smoking status | ||
| Past smoker | 13 (15) | 12 (16) |
| Current smoker | 7 (8) | 4 (5) |
| Long-term relationshipd | 63 (74) | 52 (70) |
| Sexually active | 59 (69) | 59 (80) |
| Body mass index | 25.9 (22.1-30.1) | 26.5 (23.8-30.0) |
| Hb, g/L | 136 (127-144) | 154 (144-162) |
| Baseline anemia (Hb <130 g/L men, Hb <120 g/L women) | 7 (8) | 4 (5) |
| Active endoscopic disease (SES-CD ≥3, UCEIS ≥2) | 50 (59) | 40 (54) |
| Active symptoms (HBI ≥5, UCEIS ≥5) | 58 (68) | 35 (47) |
| CRP, mg/L | 3.0 (0.0-7.8) | 0.0 (0.0-5.8) |
| Patients with CRP >3 mg/L | 44 (52) | 35 (47) |
| fCal, µg/g | 111.1 (31.9-332.6) | 147.6 (70.1-602.4) |
| Patients with fCal ≥200 µg/g | 30 (35) | 29 (39) |
| Moderate-severe stress symptoms (PSS-10 ≥14) | 50 (59) | 28 (38) |
| Severe depressive symptoms (PHQ-9 ≥10) | 36 (42) | 15 (20) |
| Severe anxiety symptoms (GAD-7 ≥10) | 23 (27) | 12 (16) |
Values are n (%) or median (interquartile range).
Abbreviations: CRP, C-reactive protein; fCal, fecal calprotectin; GAD-7, Generalized Anxiety Disorder-7; Hb, hemoglobin; HBI, Harvey-Bradshaw index; PHQ-9, Patient Health Questionnaire-9; PSS-10, Perceived Stress Scale 10; SCCAI, Simple Clinical Colitis Activity Index; SES-CD, Simple Endoscopic Score for Crohn’s Disease; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.
aChronic respiratory, cardiac, gastrointestinal (excluding inflammatory bowel disease and irritable bowel syndrome), gynecological condition, or current/previous malignancy (excluding squamous cell skin cancer or basal cell skin cancer).
bActive fissure, fistula, or abscess (Crohn’s disease only).
c≥14 units/week for women, ≥21 units/week for men.
dSelf-reported relationship for >1 year.